Fig. 3.

Overexpression of EGFL9 promotes distant tumor metastasis in vivo. a Overexpression of EGFL9 in EpRas cells did not change tumor weight. EpRas/LacZ cells serve as a control model (NS, P = 0.59). b Quantification of metastatic lesions in two groups of tumors derived from EpRas/LacZ and EpRas/EGFL9 cells implanted in NCR nu/nu mice. Average metastatic lesion numbers from five serial sections in each tumor were compared. ***P < 0.001. P values were determined by unpaired two-tailed t-test. c Quantification of metastasis by lesion area in two groups of tumors derived from EpRas/LacZ and EpRas/EGFL9 cells implanted in NCR nu/nu mice. Relative metastatic lesion areas (tumor lesion/lung section) from sections with the highest metastatic lesion number in each tumor were compared. ***P < 0.001. P values were determined by unpaired two-tailed t-test. d Representative H&E staining pictures of lung sections from mice. IHC results showed significant metastatic lesions in EGFL9 transfected EpRas cells (low panel) in comparison with EpRas transfected with LacZ (top panels). Magnification: ×40 (left panels) and ×400 (right panels). Scale bar: 200 µm